Compass Therapeutics在2026年第一季度每股下跌0.09美元，略高预期。 Compass Therapeutics lost $0.09 per share in Q1 2026, slightly beating expectations.

Compass Therapeutics公布2026年第一季度盈利每股亏损0.09美元，略高于预期的0.10美元。 Compass Therapeutics reported Q1 2026 earnings with a loss of $0.09 per share, slightly better than the expected $0.10. 开发免疫瘤药物CTX-471和DSP107的剑桥生物技术公司在3月5日的股价上市时为5.53美元,市值为9.8357亿美元,收益率为-12.29%. The Cambridge-based biotech, developing immuno-oncology drugs like CTX-471 and DSP107, saw its stock open at $5.53 on March 5, with a market cap of $983.57 million and a negative P/E ratio of -12.29. 分析师维持“机动购买”共识,目标为13.00美元,不过有些分析师将目标评为“销售”。 Analysts maintain a "Moderate Buy" consensus with a $13.00 target, though some rate it a "Sell." 体制所有权为68.43%。 Institutional ownership is 68.43%.